151 related articles for article (PubMed ID: 34461615)
1. Retinal Blood Flow as a Predictor of Recurrence of Macular Edema after Intravitreal Ranibizumab Injection in Central Retinal Vein Occlusion.
Takano Y; Noma H; Yasuda K; Yamaguchi T; Goto H; Shimura M
Ophthalmic Res; 2021; 64(6):1013-1019. PubMed ID: 34461615
[TBL] [Abstract][Full Text] [Related]
2. Retinal blood flow levels measured by laser speckle flowgraphy in patients who received intravitreal bevacizumab injection for macular edema secondary to central retinal vein occlusion.
Matsumoto M; Suzuma K; Fukazawa Y; Yamada Y; Tsuiki E; Fujikawa A; Kitaoka T
Retin Cases Brief Rep; 2014; 8(1):60-6. PubMed ID: 25372211
[TBL] [Abstract][Full Text] [Related]
3. Effects of Intravitreal Ranibizumab Injection to Treat Macular Edema due to Central Retinal Vein Occlusion on Choroidal Findings and Functional-Morphological Parameters.
Yasuda K; Noma H; Oyama E; Yanagida K; Asakage M; Shimura M
Ophthalmic Res; 2023; 66(1):1063-1070. PubMed ID: 37331343
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal ranibizumab improves macular sensitivity in patients with central retinal vein occlusion and macula edema.
Otawa T; Noma H; Yasuda K; Narimatsu A; Asakage M; Tanaka A; Goto H; Shimura M
BMC Ophthalmol; 2022 Jun; 22(1):247. PubMed ID: 35658906
[TBL] [Abstract][Full Text] [Related]
5. Ocular microcirculation changes, measured with laser speckle flowgraphy and optical coherence tomography angiography, in branch retinal vein occlusion with macular edema treated by ranibizumab.
Asano T; Kunikata H; Yasuda M; Nishiguchi KM; Abe T; Nakazawa T
Int Ophthalmol; 2021 Jan; 41(1):151-162. PubMed ID: 32894391
[TBL] [Abstract][Full Text] [Related]
6. Correlation between optic nerve head circulation and visual function before and after anti-VEGF therapy for central retinal vein occlusion: prospective, interventional case series.
Nagasato D; Mitamura Y; Semba K; Akaiwa K; Nagasawa T; Yoshizumi Y; Tabuchi H; Kiuchi Y
BMC Ophthalmol; 2016 Apr; 16():36. PubMed ID: 27044276
[TBL] [Abstract][Full Text] [Related]
7. Macular vessel reduction as predictor for recurrence of macular oedema requiring repeat intravitreal ranibizumab injection in eyes with branch retinal vein occlusion.
Hasegawa T; Takahashi Y; Maruko I; Kogure A; Iida T
Br J Ophthalmol; 2019 Oct; 103(10):1367-1372. PubMed ID: 30514711
[TBL] [Abstract][Full Text] [Related]
8. BETTER PROGNOSIS FOR EYES WITH PRESERVED FOVEAL DEPRESSION AFTER INTRAVITREAL RANIBIZUMAB INJECTION FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
Kitagawa S; Yasuda S; Ito Y; Ueno S; Iwase T; Terasaki H
Retina; 2018 Jul; 38(7):1354-1360. PubMed ID: 28538263
[TBL] [Abstract][Full Text] [Related]
9. Correlation between reduction in macular vessel density and frequency of intravitreal ranibizumab for macular oedema in eyes with branch retinal vein occlusion.
Hasegawa T; Murakawa S; Maruko I; Kogure-Katakura A; Iida T
Br J Ophthalmol; 2019 Jan; 103(1):72-77. PubMed ID: 29545416
[TBL] [Abstract][Full Text] [Related]
10. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.
Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M
Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
12. Twenty-Four Month Results of Intravitreal Ranibizumab for Macular Edema after Branch Retinal Vein Occlusion: Visual Outcomes and Resolution of Macular Edema.
Inagaki M; Hirano Y; Yasuda Y; Kawamura M; Suzuki N; Yasukawa T; Yoshida M; Ogura Y
Semin Ophthalmol; 2021 Oct; 36(7):482-489. PubMed ID: 33617388
[No Abstract] [Full Text] [Related]
13. Intravitreal ranibizumab (Lucentis) for treatment of central retinal vein occlusion: a prospective study.
Rouvas A; Petrou P; Vergados I; Pechtasides D; Liarakos V; Mitsopoulou M; Ladas I
Graefes Arch Clin Exp Ophthalmol; 2009 Dec; 247(12):1609-16. PubMed ID: 19609550
[TBL] [Abstract][Full Text] [Related]
14. RELATIONSHIP BETWEEN CHOROIDAL FINDINGS AND GROWTH FACTORS, CYTOKINES, AND OTHER INFLAMMATORY MEDIATORS AFTER INTRAVITREAL RANIBIZUMAB INJECTION IN PATIENTS WITH MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION.
Noma H; Yasuda K; Mimura T; Shimura M
Retina; 2022 Apr; 42(4):744-751. PubMed ID: 35350049
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion.
Ip MS; Gottlieb JL; Kahana A; Scott IU; Altaweel MM; Blodi BA; Gangnon RE; Puliafito CA
Arch Ophthalmol; 2004 Aug; 122(8):1131-6. PubMed ID: 15302652
[TBL] [Abstract][Full Text] [Related]
16. Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion.
Babiuch AS; Han M; Conti FF; Wai K; Silva FQ; Singh RP
JAMA Ophthalmol; 2019 Jan; 137(1):38-46. PubMed ID: 30286219
[TBL] [Abstract][Full Text] [Related]
17. Cytokines and Recurrence of Macular Edema after Intravitreal Ranibizumab in Patients with Branch Retinal Vein Occlusion.
Noma H; Mimura T; Yasuda K; Nakagawa H; Motohashi R; Kotake O; Shimura M
Ophthalmologica; 2016; 236(4):228-234. PubMed ID: 27832655
[TBL] [Abstract][Full Text] [Related]
18. Recurrence of macular edema in retinal vein occlusions after treatment with intravitreal ranibizumab (Lucentis).
Karagiannis DA; Karampelas MD; Soumplis VM; Amariotakis C; Georgalas I; Kandarakis A
Can J Ophthalmol; 2011 Dec; 46(6):486-90. PubMed ID: 22153634
[TBL] [Abstract][Full Text] [Related]
19. Comparison of clinical efficacy of intravitreal ranibizumab with and without triamcinolone acetonide in macular edema secondary to central retinal vein occlusion.
Fan C; Wang Y; Ji Q; Zhao B; Xie J
Curr Eye Res; 2014 Sep; 39(9):938-43. PubMed ID: 24635755
[TBL] [Abstract][Full Text] [Related]
20. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
Spooner K; Fraser-Bell S; Hong T; Chang A
Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
